SCN1A and Dravet syndrome: In contrast, we demonstrate that a single bilateral ICV administration of AAV9-REGABA-eTFSCN1A at PND1 leads to both a significant reduction in HTS sensitivity and extended survival in two distinct genetic mouse models of DS (Scn1a+/− and Scn1a+/R1407X).